Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Knockout Engineered T Cells for Advanced Malignant Melanoma
ChiCTR-OIC-17010391Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Jan 2017
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PD-1 knockout engineered T cells in melanoma, sponsored by The First Affiliated Hospital of USTC. Primary endpoint: Safety and tolerability of PD-1 knockout T cells. Started Jan 2017; status: recruiting.
02
Drugs
PD-1 knockout engineered T cells
03
Conditions
melanoma
Beyond the preview
Go deeper on ChiCTR-OIC-17010391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-17010391.